ArticleScientific reports2026
The prognostic significance of metastasis to No. 253 lymph node in stage III rectal cancer based on a bicenter retrospective study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This bicenter study evaluates the prognostic value of No.253 lymph node metastasis and establishes a dynamic prediction model for stage III rectal cancer. Retrospective analysis included 956 pTNM III stage rectal cancer patients undergoing radical resection (2016-2024) at two tertiary centers. Propensity score matching (PSM, 1:4 ratio) balanced baseline characteristics between No.253-positive (n = 78) and negative (n = 260) cohorts. Before PSM, the No.253 metastasis rate for stage III rectal cancer was 8.3%, multivariate Cox regression analysis showed that No.253 lymph node metastasis was an independent risk factor for OS (HR = 2.780, 95% CI: 1.874-4.124, P < 0.001). Furthermore, after PSM, the median follow-up period was 32.0 months (range: 1.0 to 92.0 months). The 3-year overall survival rate was 60.6% in the positive group and 81.7% in the negative group (P < 0.001). Multivariate Cox regression identified No.253 involvement as an independent OS determinant (HR = 3.171, 95% CI 2.016-4.986, P < 0.0011), alongside sex, circumferential resection margin (CRM) positivity and advanced pTNM stage. The developed dynamic nomograms, directly accessible at URL: https://pcrpredict.shinyapps.io/No253/ , showed strong predictive accuracy (1-/3-/5-year C-indices: 0.741/0.719/0.738), maintained across external validation cohorts (Zhangzhou: 0.816/0.649/0.619; Union: 0.726/0.674/0.647). Decision curve analysis confirmed clinical utility. No.253 Lymph node status has a significant impact on long-term prognosis after surgery for stage III rectal cancer. The validated web-based model enables personalized prognosis prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.